NASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free RGEN Stock Alerts $167.05 +0.74 (+0.44%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$166.43▼$172.0050-Day Range$157.06▼$199.7452-Week Range$110.45▼$211.13Volume454,984 shsAverage Volume538,521 shsMarket Capitalization$9.33 billionP/E Ratio668.23Dividend YieldN/APrice Target$197.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Repligen alerts: Email Address Repligen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside18.4% Upside$197.75 Price TargetShort InterestBearish8.85% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment0.05Based on 26 Articles This WeekInsider TradingSelling Shares$5.04 M Sold Last QuarterProj. Earnings Growth41.78%From $1.46 to $2.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.01 out of 5 starsMedical Sector189th out of 904 stocksBiological Products, Except Diagnostic Industry20th out of 153 stocks 2.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRepligen has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.85% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Repligen has recently decreased by 3.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 68.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.33. Previous Next 2.2 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Repligen this week, compared to 5 articles on an average week.Search Interest3 people have searched for RGEN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 5 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,039,532.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 41.78% in the coming year, from $1.46 to $2.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 668.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 126.72.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 668.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 143.52.Price to Earnings Growth RatioRepligen has a PEG Ratio of 5.46. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. About Repligen Stock (NASDAQ:RGEN)Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More RGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGEN Stock News HeadlinesMay 4, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Repligen Co. Cut by William Blair (NASDAQ:RGEN)May 4, 2024 | americanbankingnews.comLeerink Partnrs Analysts Increase Earnings Estimates for Repligen Co. (NASDAQ:RGEN)May 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.May 3, 2024 | finance.yahoo.comRepligen First Quarter 2024 Earnings: EPS Misses ExpectationsMay 2, 2024 | finance.yahoo.comRepligen Corporation (NASDAQ:RGEN) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comRepligen Corp (RGEN) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Shifts and ...May 2, 2024 | gurufocus.comQ1 2024 Repligen Corp Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comRepligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment with Analyst ProjectionsMay 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.May 1, 2024 | investorplace.comRGEN Stock Earnings: Repligen Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | msn.comRepligen reports mixed Q1 results; reaffirms FY24 outlookMay 1, 2024 | globenewswire.comRepligen Reports First Quarter 2024 Financial ResultsApril 29, 2024 | nasdaq.comRGEN Quantitative Stock AnalysisApril 25, 2024 | americanbankingnews.comRepligen (NASDAQ:RGEN) Shares Gap Up to $157.48April 23, 2024 | finance.yahoo.comShould be Confident in Repligen Corporation (RGEN)’s Long-Term Growth Potential?April 19, 2024 | markets.businessinsider.comPositive Report for Repligen (RGEN) from Craig-HallumApril 18, 2024 | nasdaq.comRepligen Corporation Common Stock (RGEN)April 17, 2024 | finance.yahoo.comRepligen to Report First Quarter 2024 Financial ResultsApril 17, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - RGENApril 12, 2024 | finance.yahoo.comArtisan Mid Cap Fund Trimmed Repligen Corporation (RGEN) after Share AppreciationApril 9, 2024 | markets.businessinsider.comRBC Capital Remains a Buy on Repligen (RGEN)March 19, 2024 | globenewswire.comRepligen Appoints Maggie A. Pax to Board of DirectorsMarch 18, 2024 | finance.yahoo.comAre Repligen Corporation's (NASDAQ:RGEN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?March 16, 2024 | finance.yahoo.comRGEN Apr 2024 150.000 callMarch 12, 2024 | finance.yahoo.comRepligen Corp CEO Anthony Hunt Sells 16,707 SharesFebruary 28, 2024 | morningstar.comRepligen Corp RGENFebruary 27, 2024 | finance.yahoo.comRepligen Corp COO James Bylund Sells 4,373 SharesSee More Headlines Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/05/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,783Year Founded1981Price Target and Rating Average Stock Price Target$197.75 High Stock Price Target$220.00 Low Stock Price Target$170.00 Potential Upside/Downside+18.4%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.25 Trailing P/E Ratio668.23 Forward P/E Ratio114.42 P/E Growth5.46Net Income$41.58 million Net Margins2.44% Pretax Margin4.96% Return on Equity3.95% Return on Assets2.90% Debt Debt-to-Equity Ratio0.26 Current Ratio6.35 Quick Ratio5.75 Sales & Book Value Annual Sales$638.76 million Price / Sales14.61 Cash Flow$3.03 per share Price / Cash Flow55.21 Book Value$35.27 per share Price / Book4.74Miscellaneous Outstanding Shares55,880,000Free Float55,205,000Market Cap$9.33 billion OptionableOptionable Beta1.03 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Anthony J. Hunt (Age 60)CEO & Director Comp: $885kMr. Olivier Loeillot (Age 54)President & Chief Commercial Officer Comp: $1.49MMr. Jason K. Garland (Age 50)CFO & Chief Compliance Officer Comp: $282.99kMr. James R. Bylund (Age 60)Chief Operating Officer Comp: $472.18kMs. Christine Gebski (Age 56)Senior Vice President of Filtration & Chromatography Comp: $396.09kMr. Ralf Kuriyel (Age 66)Senior Vice President of Research & Development Comp: $401.74kMr. Keith Lee RobinsonChief Information OfficerMs. Sondra S. NewmanGlobal Head of Investor RelationsMs. Kimberly A. CornwellGeneral Counsel & Global Head of LegalDr. Jaime M. Humara Ph.D.Senior Vice President of Global MarketingMore ExecutivesKey CompetitorsAcceleron PharmaNASDAQ:XLRNExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALONeurocrine BiosciencesNASDAQ:NBIXDenali TherapeuticsNASDAQ:DNLIView All CompetitorsInsiders & InstitutionsGeneva Capital Management LLCSold 1,449 shares on 5/4/2024Ownership: 0.212%BI Asset Management Fondsmaeglerselskab A SBought 1,806 shares on 5/3/2024Ownership: 0.005%Central Pacific Bank Trust DivisionBought 2,743 shares on 5/3/2024Ownership: 0.005%Mutual of America Capital Management LLCSold 1,144 shares on 5/2/2024Ownership: 0.058%Fidelis Capital Partners LLCBought 625 shares on 5/2/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions RGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Repligen stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks. What is Repligen's stock price target for 2024? 9 analysts have issued 12-month target prices for Repligen's stock. Their RGEN share price targets range from $170.00 to $220.00. On average, they predict the company's share price to reach $197.75 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts. How have RGEN shares performed in 2024? Repligen's stock was trading at $179.80 on January 1st, 2024. Since then, RGEN shares have decreased by 7.1% and is now trading at $167.05. View the best growth stocks for 2024 here. When is Repligen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our RGEN earnings forecast. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) released its earnings results on Wednesday, May, 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by $0.01. The biotechnology company had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a trailing twelve-month return on equity of 3.95% and a net margin of 2.44%. The business's revenue was down 17.1% on a year-over-year basis. During the same quarter last year, the company earned $0.64 earnings per share. What ETFs hold Repligen's stock? ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), BNY Mellon Innovators ETF (BKIV), Fidelity Disruptive Medicine ETF (FMED), Congress SMid Growth ETF (CSMD), VanEck Biotech ETF (BBH) and Nuveen ESG Mid-Cap Growth ETF (NUMG). What guidance has Repligen issued on next quarter's earnings? Repligen issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). Who are Repligen's major shareholders? Repligen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (2.03%), Conestoga Capital Advisors LLC (1.34%), Riverbridge Partners LLC (0.80%), Principal Financial Group Inc. (0.62%), Allspring Global Investments Holdings LLC (0.60%) and Allspring Global Investments Holdings LLC (0.60%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More This page (NASDAQ:RGEN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldCharles Payne Demystifies OptionsUnstoppable ProsperityThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.